Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Imagenetix reports promising in vitro data for inflammation compound
Among the main findings is that 1-tetradecanol complex (1-TDC) significantly inhibited the growth of actinomyces viscosus, a microbe that has been shown to play a major role in
Among the main findings is that 1-tetradecanol complex (1-TDC) significantly inhibited the growth of actinomyces viscosus, a microbe that has been shown to play a major role in
Pirfenidone is the company’s small molecule drug candidate that is being developed for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in its phase III program, named
Under the terms of the agreements, Pfizer will invest $25 million in Monogram through a 3% senior secured convertible note, payable in May 2010. The investment, which is
The objective of the phase I small business innovation research (SBIR) grant is to demonstrate the feasibility of using AvidBiotics’ proprietary technology to build customized antibacterial therapeutics, prophylactics
Results from the trial also show that patients who remained in the study and were on Copaxone had a relapse rate reduction of more than 80% over a
While vancomycin is highly potent against free living or planktonic MRSA bacteria, it is unable to eradicate the MRSA bacteria in the form of biofilms. In contrast, CSA-13
Endovasc has submitted its protocol for the phase IIIa clinical trial of the drug to the FDA, and hopes to initiate the trial later this year. Intermittent claudication,
Led by senior management from the advisors and consultants staff, within the Center for Drug Evaluation and Research (CDER), this examination of current practices will include the processes
The MHRA investigation allegedly comes after the charity Adverse Psychiatric Reactions Information Link (April) submitted a dossier of adverse event reports. According to April, there are hundreds of
Cytogen will no longer pay Berlex a royalty on Quadramet sales in exchange for an upfront cash payment of $6 million and the issuance of 623,441 shares of